Aeras Global TB Vaccine Foundation and SSI enter vaccine collaboration  

US based Aeras Global TB Vaccine Foundation and Statens Serum Institut have entered a collaboration to develop SSI's tuberculosis (TB) vaccine, HyVac4

US based, Aeras Global TB Vaccine Foundation and Statens Serum Institut (SSI), a Danish state owned company engaged in prevention and control of infectious diseases, have announced a new collaboration on pre-clinical and clinical development of SSI's tuberculosis (TB) vaccine, HyVac4. Aeras and SSI will form a joint product development team, and Aeras will provide the funding.


Under the terms of the agreement, SSI's subunit HyVac4 TB vaccine candidate will be developed as a booster vaccine to extend the protection of the currently available TB vaccine, Bacillus Calmette-Guérin (BCG).


Dr. Jerald Sadoff, President and CEO of Aeras says: "TB kills 2 million people each year – one death every 15 seconds. It is the world's second biggest killer among infectious diseases and responsible for one in three HIV related deaths. A new vaccine is the best hope to defeat this terrible disease. Statens Serum Institut and Dr. Peter Andersen's group are among the world leaders in the development of novel TB vaccines. We look forward to working together to develop this very promising vaccine candidate."


The Bill and Melinda Gates Foundation last year awarded Aeras a USD 82.9 mn grant for new TB vaccine development. Aeras aims to work with leading public and private sector organisations worldwide to bring an improved TB vaccine to market in the next 7-10 years. "We wish to thank Denmark's Ministry of Foreign Affairs, Invest in Denmark and Copenhagen Capacity with whom Aeras has been working closely throughout this process", Aeras states in a press release.


The news is reported on SSI's website.


Link > Aeras

Link > SSI

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×